The Top 5 Biosimilars Articles for the Week of September 25

The Center for Biosimilars Staff

The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of September 25, 2017.

Transcript:

Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of September 25.

Number 5: With the Graham-Cassidy bill dead in the Senate, efforts at healthcare reform have turned to the issue of the high cost of prescription drugs.

Number 4: The European Medicines Agency has warned that it could lose 94% of its staff when it is forced to relocate from its current home in London as the United Kingdom finalizes its withdrawal from the European Union.

Number 3: Celltrion and Teva’s rituximab biosimilar CT-P10, currently under review by the FDA, shows comparable safety and efficacy to its reference, Rituxan, in a new network meta-analysis.

Number 2: Amgen has filed a new Biologics Price Competition and Innovation Act lawsuit against rival drug maker, Mylan. Amgen asserts that Mylan infringed on 2 patents covering Neulasta when it developed its pegfilgrastim biosimilar.

Number 1: AbbVie, maker of Humira, has reached a settlement with Amgen concerning its adalimumab biosimilar, Amgevita. The agreement clears the way for the biosimilar to launch in the European Union in 2018, and in the United States in 2023.

Finally, last week, our newsletter for your input on what factors will determine clinical uptake of the newly approved bevacizumab biosimilar. To view results of our poll, visit The Center for Biosimilars® on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.